Gravar-mail: The Low Incidence of Secondary Acute Myelogenous Leukemia in Children and Adolescents Treated with Dexrazoxane for Acute Lymphoblastic Leukemia: A Report from the Dana-Farber Cancer Institute ALL Consortium